Screener
Mineralys Therapeutics, Inc. MLYS Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | Three Months Ended / March 31, 2026 | 2025 |
|---|---|---|
| General and administrative | 20,975 | 6,568 |
| Total operating expenses | 45,340 | 44,447 |
| Loss from operations | (45,340) | (44,447) |
| Interest income, net | 5,996 | 2,239 |
| Other income (expense) | 5 | (3) |
| Total other income, net | 6,001 | 2,236 |
| Net loss | $(39,339) | $(42,211) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.47) | $(0.79) |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s interest expense?
- Mineralys Therapeutics, Inc. (MLYS) reported interest expense of $6M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s interest expense changed year-over-year?
- Mineralys Therapeutics, Inc.'s interest expense increased by 167.8% year-over-year, from $2.24M to $6M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s interest expense?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s interest expense has grown at a 111.9% compound annual growth rate (CAGR), from $1.68M to $15.95M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Mineralys Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude